business
Elan rejects Royalty Pharma’s ‘grossly undervaluing’ €7bn takeover approach
Elan has rejected Royalty Pharma’s near €7bn takeover approach, saying the offer substantially undervalues the company and doesn’t account for the Irish firm’s future prospects.
